Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nice!! not tough to say that with future knowledge that has already been given us $HIRU holders!! :) lol
Emerging Growth Conference Regen BioPharma, Inc. (OTC Pink: RGBP), (OTC Pink: RGBPP)
MobileSavior.com :) <3
Love you all!!! Jesus is my Lord and Savior!!! :)
Love you all!!! Jesus is my Lord and Savior!!! :)
Love you all!!! Jesus is my Lord and Savior!!! :)
Videmoji.com :) :) ;) <3
TheBeautifulPrincess.com ) :) :) :) :) :) :)
olivejuice.love :) :) :)
mobilelegacies.com :) :)
OMG!!! sure could be!! :) And maybe $TLSS can arrange trucks for HIRU??? :) :) :)
Love to all!!
Love!!
$RGBP !!! :)
$GSTC !!! :)
TWEET We’re committed to expanding awareness about our IsoPet® Therapy for animals suffering from tumors.
Sharing information from one #veterinarian to another is crucial to demonstrate how our device technology can save more #pet lives. Dr. Heidrich will be a great resource. $RDGL
We’re committed to expanding awareness about our IsoPet® Therapy for animals suffering from tumors.
— Vivos Inc. (@VivosIncUSA) December 30, 2022
Sharing information from one #veterinarian to another is crucial to demonstrate how our device technology can save more #pet lives. Dr. Heidrich will be a great resource. $RDGL https://t.co/PGuNdHfs99
TWEETS December 29, 2022 Dr. John E. Heidrich, PHD, VCM joins our Veterinary Medicine Advisory Board
Dr. John E. Heidrich, Ph.D., VCM, joined our Veterinary Medicine Advisory Board, chaired by Dr. Alice Villalobos.
He recently retired as co-owner of VCA Ventana Animal Hospital in Albuquerque, NM. He brings senior practical experience in veterinary medicine and will be particularly helpful in locating patients for IsoPet® therapy.
He recently accompanied us at our booth at the 68th Annual Convention of the American Association of Equine Practitioners, AAEP, in San Antonio, Texas.
1). Dr. John E. Heidrich, Ph.D., VCM, joins our Veterinary Medicine Advisory Board, chaired by Dr. Alice Villalobos.
— IsoPet® Cancer Treatment (@IsoPetForCancer) December 29, 2022
He accompanied us at the 68th Annual Convention of the American Association of Equine Practitioners, AAEP, in San Antonio, Texas.https://t.co/9d1hTrMlFN
$RDGL !!! :)
we all have our separate lives....... needs, hurts, loves, wants, ......... Jesus is with us in every one!!!!!!!!!!!! amazing I am discovering so much of these things so late in my life!! Love U all!! :)
we all have our separate lives....... needs, hurts, loves, wants, ......... Jesus is with us in every one!!!!!!!!!!!! amazing I am discovering so much of these things so late in my life!! Love U all!! :)
TWEET** Focusing on HIRU for 2023 and stepping down as CEO for NXMR, one job one focus and will continue to push product out the door to the major store brands. $HIRU
11:23 AM · Dec 27, 2022
Focusing on HIRU for 2023 and stepping down as CEO for NXMR, one job one focus and will continue to push product out the door to the major store brands. $HIRU
— @Hirucorp (@Hirucorpnew) December 27, 2022
Love to all!!!, no matter what!!! Bless all in Jesus! :
Love to all!!!, no matter what!!! Bless all in Jesus! :) :)
So much Love from Jesus for all, no matter what!!!!! We are here temporarily till our human bodies fade away! Any time remaining for me with my human body alive???........ I promise to God first, that I will share what I know, about what I know, about Him to other people!!! AND... Love and help others when I can!!! :) :) :)
P.S. Yes! My birthday is: 12/25/1963 :)
So much Love from Jesus for all, no matter what!!!!! We are here temporarily till our human bodies fade away! Any time remaining for me with my human body alive???........ I promise to God first, that I will share what I know, about what I know, about Him to other people!!! AND... Love and help others when I can!!! :) :) :)
P.S. Yes! My birthday is: 12/25/1963 :)
So much Love from Jesus for all, no matter what!!!!! We are here temporarily till our human bodies fade away! Any time remaining for me with my human body alive???........ I promise to God first, that I will share what I know, about what I know, about Him to other people!!! AND... Love and help others when I can!!! :) :) :)
P.S. Yes! My birthday is: 12/25/1963 :)
Amen!!! :) :) :)
NYBOB!!!!!!! your posts contain WAYYYY TOOO MUCH angst and scary things! Just wanna say please be at peace? What you post in here is helping?????????????????????
NYBOB!!!!!!! your posts contain WAYYYY TOOO MUCH angst and scary things! Just wanna say please be at peace
NYBOB!!!!!!! your posts contain WAYYYY TOOO MUCH angst and scary things! Just wanna say please be at peace
$HIRU !!! :) :) :)
$HIRU !!! :) :) :)
Good afternoon $GSTC shareholders. We met with representatives from two hospital groups jockeying to host/accept our MS clinical trials last week in Florida. It looks favorable to get approval very soon! Both groups want to be apart of possibly rewriting MS history.
Good afternoon $GSTC shareholders. We met with representatives from two hospital groups jockeying to host/accept our MS clinical trials last week in Florida. It looks favorable to get approval very soon! Both groups want to be apart of possibly rewriting MS history.
— GlobeStar Therapeutics (@officialGSTC) December 20, 2022
ummmmm... its END OF YEAR, right????? LoL ! :) $GSTC !!! :)
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
News provided by
Regen BioPharma, Inc.
Dec 19, 2022, 16:58 ET
Share this article
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) As 2022 comes to a close, I would like to highlight some our many accomplishments achieved this year and also to respond to the multiple queries regarding future business strategy and planning that we have received.
We significantly strengthened and broadened our intellectual property portfolio this year. We accomplished this by filing 4 new patents applications in the areas of mRNA vaccines and CAR T-cell therapies. In addition, we had 2 patents issued by the US patent office which protect our composition of matter around inhibiting and activating NR2F6 using small molecules.
Our science is now progressing. While the Company has many exciting pipeline products, we need to focus our limited resources towards what we believe will provide patients and our shareholders the maximum benefit. Thus, we are actively developing a novel CAR T-cell therapy which we call DuraCAR. This cell therapy is designed to utilize our patented shRNA that targets the immune checkpoint NR2F6 in the context of a CAR T-cell. By doing so, we expect that this cell therapy will be able to kill solid tumors as well as leukemias and lymphomas because these cells should be less susceptible to exhaustion and immunosuppression by the tumor microenvironment. We expect additional results from our partner CROs in the coming months. As this program progresses, we will seek out-licensing or asset sale opportunities to progress this product into the clinic.
To support this program, we are delighted that two accomplished scientists from the University of Pennsylvania, Dr. Ravinder Reddy and Dr. Mohammad Haris, have chosen to join our Scientific Advisory Board. The Company will rely on their expertise in CAR T-cell therapy and their understanding of the basic mechanisms by which CAR T-cells function to help with experimental design and interpretation.
Regarding financing, we dramatically reduced our convertible debt this year from $3,024,080 in principal and $652,905 in accrued interest as of March 31, 2022 to currently an outstanding balance of $510,000 principal and $250,859 in accrued interest in 2022. We are acutely aware that funding the company through debt is the least attractive option and therefore are currently exploring other financing options to support our scientific programs and to add to our management team.
Once we raise sufficient funds, expanding our management team will be a priority item for us. We believe adding strength to our business development efforts and our clinical programs will be critical for the Company to achieve its stated goals of moving its proprietary intellectual property through Phase 1/2 clinical development before partnering with a much larger biotech or pharma company.
Finally, I want to thank each of our shareholders. We all understand that the road to successful treatments for major illnesses such as cancer is long and arduous but we accept that and plan on continuing to progress our programs into the clinic.
Happy New Year to All,
David R. Koos
Chairman & CEO
https://www.prnewswire.com/news-releases/regen-biopharma-inc-issues-message-to-the-shareholders-from-the-chairman-and-chief-executive-officer-301706524.html
$RGBP $RGBPP
— Regen BioPharma Inc. (@TheRegenBio) December 19, 2022
Chairman's letter to Regen BioPharma shareholdershttps://t.co/Sphs4v7aCx
OMG!!! My QODE account stlll works!!! lol
http://www.qode.com/